ADAURA Trial Findings: Osimertinib for EGFR-mutated NSCLC

The phase 3 ADAURA trial evaluated osimertinib versus placebo in patients with in resected stage IB–IIIA EGFR-mutant non-small cell lung cancer. The results presented at the 2023 ASCO Annual Meeting demonstrated that adjuvant osimertinib induced “an unprecedented, highly statistically significant and clinically meaningful OS benefit in patients with EGFR-mutated stage IB-IIIA NSCLC,” according to study authors.

Learn more about the impact of the ADAURA trial findings.

Read the full study published in the Journal of Clinical Oncology.